Impact of vaccination programs on the incidence of meningococcal infections

INTRODUCTION

Meningococcal infections, caused by Neisseria meningitidis, represent a significant public health concern due to their potential to cause rapid and severe diseases such as meningitis and septicemia. These infections are associated with high morbidity and mortality rates, particularly in certain at-risk populations, including young children, adolescents, and individuals with compromised immune systems. Global efforts to reduce the incidence of meningococcal disease have largely centered on the development and implementation of vaccination programs, which have shown to be one of the most effective public health interventions in controlling the spread of the disease.¹

Vaccination has played a pivotal role in lowering the incidence of meningococcal infections worldwide, with various vaccines targeting the most prevalent serogroups of N. meningitidis, including A, B, C, W, and Y. Over the years, the introduction of these vaccines has led to a significant reduction in the number of cases, particularly in regions where vaccination coverage is high.² However, challenges remain, particularly in low-resource settings and areas with suboptimal vaccination rates, where outbreaks of meningococcal disease continue to occur.

One area where meningococcal vaccination is of paramount importance is in large-scale gatherings, such as the annual Hajj pilgrimage in Saudi Arabia, which brings together millions of people from around the world. These mass gatherings create an environment conducive to the spread of infectious diseases, including meningococcal disease, due to overcrowding, close contact, and the mixing of individuals from diverse geographical locations. In response, vaccination against meningococcal disease has become a mandatory requirement for all Hajj pilgrims, contributing significantly to the prevention of outbreaks during these events.³

Additionally, herd immunity resulting from widespread vaccination has been instrumental in reducing the overall transmission of meningococcal disease, protecting not only vaccinated individuals but also those who are unvaccinated or unable to receive vaccines for medical reasons. This community-level protection is crucial in preventing large-scale outbreaks and maintaining public health.⁴ Despite these successes, continuous monitoring, vaccination program optimization, and public education remain critical to sustaining the gains achieved through vaccination. This review aims to explore the impact of vaccination programs on the incidence of meningococcal infections, focusing on the effectiveness of these programs, their role in community-level prevention, and specific challenges encountered during mass gatherings such as the Hajj.

REVIEW

The implementation of meningococcal vaccination programs has significantly impacted the incidence of meningococcal infections worldwide, particularly in countries with high vaccine coverage. The introduction of conjugate vaccines targeting various serogroups of Neisseria meningitidis has not only reduced the number of cases but also contributed to the establishment of herd immunity. Herd immunity occurs when a large portion of the population is immunized, reducing the overall transmission of the pathogen and indirectly protecting unvaccinated individuals.⁵ This has been particularly beneficial in settings such as schools and communities, where close contact can facilitate the rapid spread of meningococcal disease.

In mass gatherings like the Hajj, where millions of people converge annually, vaccination has been essential in preventing large outbreaks. Pilgrims from different parts of the world carry varying strains of N. meningitidis, increasing the risk of disease transmission. The mandatory meningococcal vaccination policy for Hajj pilgrims has proven highly effective in reducing the occurrence of meningococcal outbreaks during the pilgrimage.⁶ Despite these successes, challenges remain in achieving global vaccine coverage, particularly in low-income countries where healthcare infrastructure and resources may limit access to vaccines. Continued global efforts to enhance vaccination coverage, particularly in high-risk regions and populations, are essential to sustain progress in controlling meningococcal disease.

EFFECTIVENESS OF MENINGOCOCCAL VACCINES IN REDUCING INFECTION RATES

Meningococcal vaccines have demonstrated significant effectiveness in reducing the incidence of Neisseria meningitidis infections, particularly in regions with robust vaccination programs. Several vaccines have been developed to target different serogroups, with conjugate vaccines proving particularly successful due to their ability to induce long-lasting immunity and reduce nasopharyngeal carriage, which in turn decreases transmission rates.⁷ One of the earliest successes of meningococcal vaccination was the introduction of the serogroup C conjugate vaccine in the United Kingdom in 1999, which led to a dramatic decline in the incidence of serogroup C disease, particularly among young children and adolescents, who are considered high-risk groups.⁸ This success established a framework for future vaccine programs targeting other serogroups and demonstrated the broader impact of immunization beyond individual protection.

The introduction of quadrivalent vaccines, which target serogroups A, C, W, and Y, has further expanded the effectiveness of vaccination programs. These vaccines have been instrumental in controlling outbreaks, particularly in countries with diverse populations, such as the United States, where multiple serogroups circulate.⁹ Routine immunization programs, especially in adolescents and young adults, have significantly reduced the incidence of disease caused by these serogroups. For example, in the United States, routine meningococcal vaccination programs in adolescents, combined with booster doses, have led to a sustained decrease in the incidence of vaccine-preventable serogroups.

A key aspect of meningococcal vaccine effectiveness lies in their ability to confer herd immunity. By reducing the carriage of N. meningitidis in vaccinated individuals, the overall transmission of the bacterium within the community is decreased, indirectly protecting those who are unvaccinated or those who cannot be vaccinated for medical reasons.¹⁰ This indirect protection is critical for controlling outbreaks, particularly in high-density settings such as schools, universities, and mass gatherings. In Africa, for instance, the introduction of the MenAfriVac vaccine, targeting serogroup A, has resulted in a substantial reduction in cases within the "meningitis belt," a region highly susceptible to meningococcal outbreaks due to climatic and social factors.^2,8 While vaccine effectiveness is well established, ongoing surveillance and monitoring are crucial to address emerging challenges, such as vaccine coverage gaps in certain populations and the potential for the emergence of non-vaccine serogroups. Addressing these challenges requires a continued commitment to vaccination strategies, public health education, and access to vaccines globally.

HERD IMMUNITY AND POPULATION-LEVEL IMPACT OF VACCINATION PROGRAMS

Herd immunity is a critical aspect of meningococcal vaccination programs and plays a major role in controlling the spread of the disease at a population level. Herd immunity occurs when a sufficient proportion of the population is vaccinated, reducing the overall transmission of Neisseria meningitidis and indirectly protecting unvaccinated individuals. The success of this phenomenon is particularly evident in high-density settings such as schools, universities, and other community environments where close contact can facilitate the rapid spread of meningococcal disease. As vaccination programs expand, the collective immunity of a population can effectively curb outbreaks and protect vulnerable individuals, including infants and immunocompromised individuals who cannot be vaccinated.¹⁰

The concept of herd immunity was demonstrated following the introduction of the serogroup C meningococcal conjugate vaccine in the United Kingdom. After the vaccine was added to the national immunization schedule, there was not only a significant reduction in the incidence of serogroup C disease among vaccinated individuals but also a notable decline in unvaccinated age groups, showcasing the indirect benefits of widespread immunization.¹¹ Studies have shown that the vaccine reduces nasopharyngeal carriage of N. meningitidis, thereby decreasing the overall circulation of the bacteria in the population. This reduction in carriage is a key mechanism by which herd immunity is achieved, preventing the spread of the pathogen and protecting those who remain unvaccinated.

Meningococcal vaccination programs targeting multiple serogroups have also been instrumental in controlling outbreaks in regions like sub-Saharan Africa, where the "meningitis belt" experiences seasonal epidemics of meningococcal disease. The introduction of the MenAfriVac vaccine, targeting serogroup A, has drastically reduced the incidence of serogroup A meningitis in the region. This vaccine not only provided direct protection but also contributed to the establishment of herd immunity, leading to a decline in meningitis cases across multiple age groups.¹² The widespread use of MenAfriVac has resulted in a sustained reduction in meningococcal disease in one of the most vulnerable areas globally, highlighting the powerful impact of vaccination on public health at a population level. Herd immunity also contributes to the overall economic benefits of vaccination programs. By preventing outbreaks, healthcare systems are spared the significant costs associated with managing meningococcal disease, including hospitalizations, intensive care, and long-term care for survivors with disabilities. Widespread vaccination reduces these economic burdens, further emphasizing the importance of maintaining high vaccination coverage in populations.¹³

VACCINATION FOR MENINGOCOCCAL PREVENTION IN MASS GATHERINGS

Mass gatherings, such as religious pilgrimages, sports events, and festivals, pose unique public health challenges due to the high density of individuals from diverse geographical locations. The risk of infectious diseases, including meningococcal disease, increases significantly in such environments due to close contact, shared accommodations, and long travel distances. Meningococcal vaccination has become a cornerstone of preventive measures in these settings, particularly in events like the Hajj pilgrimage, where millions of individuals from around the world gather annually in Saudi Arabia.³ Meningococcal disease has been a recognized threat during Hajj for decades, leading to the implementation of mandatory vaccination policies for all pilgrims. Initially, vaccination targeted serogroup A, the most common cause of outbreaks during the pilgrimage. However, the emergence of other serogroups, such as W135, prompted a shift towards quadrivalent vaccines covering serogroups A, C, W, and Y.¹⁴ The Saudi Arabian government now requires proof of meningococcal vaccination for all pilgrims before granting entry for Hajj. This policy has significantly reduced the number of meningococcal cases associated with the pilgrimage, not only among vaccinated individuals but also in the broader global population as pilgrims return to their home countries.

The success of meningococcal vaccination during Hajj highlights the importance of similar measures in other mass gatherings. Events like the soccer World Cup or the Olympic Games, which draw large international crowds, also pose a risk for the spread of infectious diseases. While not all such events have mandatory vaccination policies, health authorities strongly recommend meningococcal vaccination for participants and attendees, particularly those from regions with high endemicity or previous exposure to meningococcal disease.¹⁵ In these contexts, vaccination helps prevent potential outbreaks and ensures the safety of both attendees and the wider community when they return to their countries of origin. Military deployments have also been identified as high-risk environments for meningococcal disease transmission. Historically, soldiers in close quarters, such as military camps, were particularly vulnerable to outbreaks. The introduction of mandatory meningococcal vaccination in military settings has significantly reduced the incidence of disease among service members, ensuring operational readiness and protecting the wider population.¹⁶ This success further underscores the critical role of vaccination in preventing meningococcal outbreaks during mass gatherings and other high-risk environments.

CHALLENGES AND STRATEGIES FOR INCREASING VACCINATION COVERAGE

Despite the effectiveness of meningococcal vaccines in reducing infection rates, achieving optimal vaccination coverage remains a significant challenge, particularly in low- and middle-income countries. Barriers to vaccination can be multifaceted, ranging from logistical issues such as inadequate healthcare infrastructure to cultural and socioeconomic factors that limit access to vaccines. In many regions, a lack of public awareness about the benefits of meningococcal vaccination contributes to vaccine hesitancy, further complicating efforts to increase coverage. Addressing these challenges requires targeted strategies aimed at improving both access to and acceptance of vaccination.¹⁷

One of the primary barriers to increasing vaccination coverage is the availability and affordability of vaccines. In low-resource settings, the cost of meningococcal vaccines can be prohibitive, preventing widespread access. Even with international support, such as subsidies from organizations like Gavi, the Vaccine Alliance, some countries still struggle to implement comprehensive vaccination programs due to inadequate healthcare infrastructure and logistical challenges related to vaccine distribution and storage.¹⁸ Cold chain requirements, for example, can be difficult to maintain in rural or remote areas, limiting the ability to deliver vaccines to populations most at risk of meningococcal disease.

Cultural and social factors also play a significant role in vaccination uptake. In some regions, particularly in parts of sub-Saharan Africa, misconceptions about vaccines, fears of side effects, or religious beliefs may lead to vaccine hesitancy or outright refusal. To overcome these barriers, community engagement and education are essential. Public health campaigns that involve local leaders, healthcare workers, and influencers can help to build trust in vaccination programs. Tailored messaging that addresses specific community concerns and emphasizes the safety and benefits of meningococcal vaccination has been shown to improve vaccine acceptance.¹⁹

Another challenge lies in the vaccination of adolescents and young adults, who are at higher risk of meningococcal disease but are often difficult to reach through routine vaccination programs. Strategies to improve vaccination coverage in this demographic include school-based vaccination initiatives and public health campaigns aimed at increasing awareness of the disease. In many countries, adolescent vaccination has become an essential component of meningococcal control efforts, with booster doses administered to maintain long-term immunity.²⁰ School-based vaccination programs have proven successful in reaching large numbers of adolescents, ensuring higher vaccination rates within this high-risk group. Overall, while challenges to increasing meningococcal vaccination coverage remain, addressing these barriers through a combination of financial support, public education, and targeted vaccination strategies is crucial for controlling the global burden of meningococcal disease.

CONCLUSION

Meningococcal vaccination programs have proven highly effective in reducing the incidence of meningococcal infections globally, especially in high-risk settings such as mass gatherings. Despite challenges in achieving optimal vaccine coverage, strategic efforts in public health education, infrastructure improvement, and targeted vaccination initiatives can enhance coverage and prevent future outbreaks. Continued global collaboration is essential to overcome barriers and sustain the success of meningococcal disease prevention.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: Not required

REFERENCES

1. 1. Pollard AJ, Frasch C. Development of natural immunity to Neisseria meningitidis. Vaccine. 2001;19(11-12):1327-46.
2. 2. Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines. 2009;8(7):851-61.
3. 3. Wilder-Smith A, Memish Z. Meningococcal disease and travel. Int J Antimicrobial Agents. 2003;21(2):102-6.
4. 4. Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev. 2007;31(1):3-14.
5. 5. Zahlanie YC, Hammadi MM, Ghanem ST, Dbaibo GS. Review of meningococcal vaccines with updates on immunization in adults. Human Vaccines Immunotherapeutics. 2014;10(4):995-1007.
6. 6. Al-Tawfiq J, Memish Z. The Hajj: updated health hazards and current recommendations for 2012. Eurosurveillance. 2012;17:41.
7. 7. Urwin R, Russell JE, Thompson EA, Holmes EC, Feavers IM, Maiden MC. Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immunity. 2004;72(10):5955-62.
8. 8. Trotter C, Gay N, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol Infect. 2006;134(3):556-66.
9. 9. MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. Morb Mort Wkly Rep. 2015;64(41):1171-6.
10. 10. Huels J, Clements K, McGarry L, Hill G, Wassil J, Kessabi S. Modelled evaluation of multi-component meningococcal vaccine (Bexsero®) for the prevention of invasive meningococcal disease in infants and adolescents in the UK. Epidemiology & Infection. 2014;142(9):2000-12.
11. 11. Ramsey M, Andrews N, Trotter C, Kaczmarski E, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326(7385):365-6.
12. 12. Kristiansen PA, Jørgensen HJ, Caugant DA. Serogroup A meningococcal conjugate vaccines in Africa. Expert Rev Vaccines. 2015;14(11):1441-58.
13. 13. Christensen H, Trotter CL, Hickman M, Edmunds WJ. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ. 2014;349:g5725.
14. 14. Lingani C, Bergeron-Caron C, Stuart JM, Katya F, Mamoudou HD, Olivier R, et al. Meningococcal meningitis surveillance in the African meningitis belt, 2004-2013. Clin Infect Dis. 2015;61(5):S410-5.
15. 15. Jentes ES, Poumerol G, Gershman MD, David RH, Johan L, Rosamund FL, et al. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. The Lancet Infect Dis. 2011;11(8):622-32.
16. 16. Harris CM, Wu HM, Li J, Irene HH, Adria L, Elizabeth Z, et al. Meningococcal disease in patients with human immunodeficiency virus infection: a review of cases reported through active surveillance in the United States, 2000–2008. Open Forum Infect Dis. 2016;3(4):ofw226.
17. 17. Kim TH, Johnstone J, Loeb M. Vaccine herd effect. Scand J Infect Dis. 2011;43(9):683-9.
18. 18. Greenwood B. The contribution of vaccination to global health: past, present and future. Philosophical Transactions of the Royal Society B: Biological Sci. 2014;369(1645):20130433.
19. 19. Larson HJ, Schulz WS, Tucker JD, Smith DM. Measuring vaccine confidence: introducing a global vaccine confidence index. PLoS Curr. 2015;7:ecurrents.outbreaks.ce0f6177bc97332602a8e 3fe7d7f7cc4.
20. 20. MacNeil JR, Cohn AC, Zell ER, Susanna S, Elaine M, Thomas C, et al. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatric Infectious Disease J. 2011;30(6):451-5.